Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Unmet Need – Detailed, Expanded Analysis: Relapsed or Refractory DLBCL (US/EU)

Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel therapies, including the anti-CD-19 CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), and Breyanzi (Bristol Myers Squibb). Other prominent targeted therapies include the anti-CD-19 monoclonal antibody Monjuvi / Minjuvi (MorphoSys / Incyte), the anti-CD-79 and CD-19 antibody-drug conjugates Polivy (Roche) and Zynlonta (ADC Therapeutics), and the SINE inhibitor Xpovio (Karyopharm Therapeutics). Despite the availability of these therapies, significant clinical and commercial opportunity remains for the development of more-tolerable novel therapies to improve patient outcomes and overcome the challenges associated with current therapies (e.g., logistical challenges associated with CAR T-cell therapies). Our Unmet Need module analyzes the key drivers of prescribing and assesses how emerging therapies may be able to capitalize on these opportunities.

QUESTIONS ANSWERED

  • What are the most important factors that drive hematologist-oncologists’ prescribing decisions for R/R DLBCL?
  • How do key current therapies perform on key clinical attributes for this patient population?
  • What are the prevailing areas of unmet need and hidden opportunities in this patient population?
  • What trade-offs across different clinical attributes and price are acceptable to surveyed hematologist-oncologists for a new therapy for R/R DLBCL?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 62 U.S. and 32 European hematologist-oncologists fielded in March 2023.

Key companies: Gilead, Novartis, Bristol Myers Squibb, MorphoSys / Incyte, Roche, ADC Therapeutics, Karyopharm Therapeutics.

Key drugs: Rituximab, Monjuvi / Minjuvi, Polivy, Zynlonta, Xpovio, Kymriah, Yescarta, Breyanzi.

Table of contents